Stay updated with breaking news from Remegen Co. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
YANTAI, China, June 3, 2024 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center
RemeGen Co. Ltd. Class H (HK:9995) has released an update. RemeGen Co., Ltd. has announced its 2023 Annual General Meeting (AGM) scheduled for June...
/PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced significant...
This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.
YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with